lorazepam has been researched along with Recrudescence in 43 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The resurgence of catatonia following tapering of lorazepam is a common clinical phenomenon." | 7.85 | Resurgence of catatonia following tapering or stoppage of lorazepam - A case series and implications. ( Ali, SF; Gowda, GS; Jaisoorya, TS; Math, SB, 2017) |
| "Clinical question Is intravenous (IV) lorazepam superior to IV diazepam in the treatment of pediatric status epilepticus? Article chosen Chamberlain JM, Okada P, Holsti M, et al." | 7.83 | Lorazepam v. diazepam for pediatric status epilepticus. ( Pinto, RF; Turnbull, J, 2016) |
| "The authors describe four cases of catatonia in which topiramate treatment was used." | 7.73 | Topiramate effect in catatonia: a case series. ( McDaniel, WW; Sahota, AK; Spiegel, DR, 2006) |
| " The speech catatonic symptoms, previously refractory to various antipsychotics, responded promptly to lorazepam, a benzodiazepine with documented efficacy in the treatment of acute catatonia but not chronic catatonia." | 7.72 | Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report. ( Lee, JW, 2004) |
| "Seven neonatal patients with severe seizures unresponsive to conventional anticonvulsant therapy were treated with lorazepam." | 7.67 | Lorazepam in the treatment of refractory neonatal seizures. A pilot study. ( Deshmukh, A; Mangurten, HH; Schnitzler, E; Wittert, W, 1986) |
| "This double-blind, randomized, noninferiority trial compared the efficacy of intramuscular midazolam with that of intravenous lorazepam for children and adults in status epilepticus treated by paramedics." | 5.16 | Intramuscular versus intravenous therapy for prehospital status epilepticus. ( Barsan, W; Conwit, R; Durkalski, V; Lowenstein, D; Palesch, Y; Pancioli, A; Silbergleit, R, 2012) |
| "The resurgence of catatonia following tapering of lorazepam is a common clinical phenomenon." | 3.85 | Resurgence of catatonia following tapering or stoppage of lorazepam - A case series and implications. ( Ali, SF; Gowda, GS; Jaisoorya, TS; Math, SB, 2017) |
| "Clinical question Is intravenous (IV) lorazepam superior to IV diazepam in the treatment of pediatric status epilepticus? Article chosen Chamberlain JM, Okada P, Holsti M, et al." | 3.83 | Lorazepam v. diazepam for pediatric status epilepticus. ( Pinto, RF; Turnbull, J, 2016) |
| "Patients with catatonia who had more than one episode of catatonia and were treated with the lorazepam-diazepam protocol were identified." | 3.83 | Relapses and recurrences of catatonia: 30-case analysis and literature review. ( Huang, TL; Hung, YY; Lin, CC; Tsai, MC, 2016) |
| "The authors describe four cases of catatonia in which topiramate treatment was used." | 3.73 | Topiramate effect in catatonia: a case series. ( McDaniel, WW; Sahota, AK; Spiegel, DR, 2006) |
| " The speech catatonic symptoms, previously refractory to various antipsychotics, responded promptly to lorazepam, a benzodiazepine with documented efficacy in the treatment of acute catatonia but not chronic catatonia." | 3.72 | Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report. ( Lee, JW, 2004) |
| "Seven neonatal patients with severe seizures unresponsive to conventional anticonvulsant therapy were treated with lorazepam." | 3.67 | Lorazepam in the treatment of refractory neonatal seizures. A pilot study. ( Deshmukh, A; Mangurten, HH; Schnitzler, E; Wittert, W, 1986) |
| "Phenobarbital and LZ were similarly effective in the treatment of mild/moderate alcohol withdrawal in the ED and at 48 hours." | 2.76 | A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. ( Barnes, RL; Dery, RA; Hendey, GW; Mentler, P; Snowden, B, 2011) |
| "Post-treatment, gabapentin-treated participants had less probability of drinking during the follow-up post-treatment period (p = 0." | 2.74 | A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. ( Anton, RF; Becker, HC; Boyle, E; Malcolm, R; Myrick, H; Randall, CL; Randall, PK, 2009) |
| " Safety was assessed through physical examinations, monitoring of vital signs, 12-lead electrocardiograms, laboratory analyses, and adverse event monitoring." | 2.69 | Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. ( Campbell, GM; Carter, FJ; Fresquet, A; Lloret, A; Marion-Landais, G; Murphy, MF; Sust, M, 2000) |
| "Sequelae and risk for recurrence of SE are primarily related to the underlying cause." | 2.39 | Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. ( Mitchell, WG, 1996) |
| "Risperidone treatment was begun (1mg/d and 1." | 1.39 | [Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms]. ( Askenazy, F; Drici, M; Lavrut, T; Menard, ML; Yagoubi, F, 2013) |
| "We present a case of catatonia associated with hyponatremia treated with a course of electroconvulsive therapy." | 1.38 | Catatonia associated with hyponatremia treated with electroconvulsive therapy. ( Aggarwal, M; Grover, S; Kattharaghatta Girigowda, V; Malhotra, N, 2012) |
| "Three patients had exceptionally high seizure threshold, as determined by an empirical titration procedure." | 1.29 | Exceptionally high seizure threshold: ECT device limitations. ( Devanand, DP; Lisanby, SH; Mullen, L; Nobler, MS; Prudic, J; Sackeim, HA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 9 (20.93) | 18.2507 |
| 2000's | 14 (32.56) | 29.6817 |
| 2010's | 16 (37.21) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Herrera-Huerta, CA | 1 |
| Hernández-Salas, LP | 1 |
| Magallanes-Cano, EM | 1 |
| Kaur, M | 1 |
| Floyd, AE | 1 |
| Ali, SF | 1 |
| Gowda, GS | 1 |
| Jaisoorya, TS | 1 |
| Math, SB | 1 |
| Hadar, R | 1 |
| Edemann-Callesen, H | 1 |
| Hlusicka, EB | 1 |
| Wieske, F | 1 |
| Vogel, M | 1 |
| Günther, L | 1 |
| Vollmayr, B | 1 |
| Hellweg, R | 1 |
| Heinz, A | 1 |
| Garthe, A | 1 |
| Winter, C | 1 |
| Grover, S | 2 |
| Parakh, P | 1 |
| Sharma, A | 1 |
| Rao, P | 1 |
| Modi, M | 1 |
| Kumar, A | 1 |
| Kasper, S | 1 |
| Iglesias-García, C | 1 |
| Schweizer, E | 1 |
| Wilson, J | 1 |
| DuBrava, S | 1 |
| Prieto, R | 1 |
| Pitman, VW | 1 |
| Knapp, L | 1 |
| Smith, DL | 1 |
| Roberts, C | 1 |
| del Río-Casanova, L | 1 |
| Portela, B | 1 |
| Díaz-Llenderrozas, F | 1 |
| Pinto, RF | 1 |
| Turnbull, J | 1 |
| Van Ameringen, M | 1 |
| Patterson, B | 1 |
| Lin, CC | 1 |
| Hung, YY | 1 |
| Tsai, MC | 1 |
| Huang, TL | 1 |
| Thamizh, JS | 1 |
| Harshini, M | 1 |
| Selvakumar, N | 1 |
| Bharadwaj, B | 1 |
| Menon, V | 1 |
| Wheless, JW | 1 |
| Marchione, P | 1 |
| Vento, C | 1 |
| Marianetti, M | 1 |
| Romeo, T | 1 |
| Amabile, GA | 1 |
| Giacomini, P | 1 |
| Myrick, H | 2 |
| Malcolm, R | 2 |
| Randall, PK | 1 |
| Boyle, E | 1 |
| Anton, RF | 2 |
| Becker, HC | 1 |
| Randall, CL | 1 |
| Manjunatha, N | 1 |
| Mehta, UM | 1 |
| John, P | 1 |
| Chèze, M | 1 |
| Muckensturm, A | 1 |
| Hoizey, G | 1 |
| Pépin, G | 1 |
| Deveaux, M | 1 |
| Hendey, GW | 1 |
| Dery, RA | 1 |
| Barnes, RL | 1 |
| Snowden, B | 1 |
| Mentler, P | 1 |
| Enterman, JH | 1 |
| van Dijk, D | 1 |
| Silbergleit, R | 1 |
| Durkalski, V | 1 |
| Lowenstein, D | 1 |
| Conwit, R | 1 |
| Pancioli, A | 1 |
| Palesch, Y | 1 |
| Barsan, W | 1 |
| Kattharaghatta Girigowda, V | 1 |
| Aggarwal, M | 1 |
| Malhotra, N | 1 |
| Menard, ML | 1 |
| Yagoubi, F | 1 |
| Drici, M | 1 |
| Lavrut, T | 1 |
| Askenazy, F | 1 |
| Lee, JW | 1 |
| Srihari, VH | 1 |
| Lee, TS | 1 |
| Rohrbaugh, RM | 1 |
| D'Souza, DC | 1 |
| McDaniel, WW | 1 |
| Spiegel, DR | 1 |
| Sahota, AK | 1 |
| Rodriguez, LJ | 1 |
| Rasmussen, KG | 1 |
| Mueller, M | 1 |
| Knapp, RG | 1 |
| Husain, MM | 1 |
| Rummans, TA | 1 |
| Sampson, SM | 1 |
| O'Connor, MK | 1 |
| Petrides, G | 1 |
| Fink, M | 1 |
| Kellner, CH | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Romach, M | 1 |
| Busto, U | 1 |
| Somer, G | 1 |
| Kaplan, HL | 1 |
| Sellers, E | 1 |
| Kanofsky, JF | 1 |
| Lindenmayer, JP | 1 |
| Konafsky, D | 1 |
| Mitchell, WG | 1 |
| Lisanby, SH | 1 |
| Devanand, DP | 1 |
| Nobler, MS | 1 |
| Prudic, J | 1 |
| Mullen, L | 1 |
| Sackeim, HA | 1 |
| Lugaresi, E | 1 |
| Montagna, P | 1 |
| Tinuper, P | 1 |
| Plazzi, G | 1 |
| Gallassi, R | 1 |
| Rosenfeld, MJ | 1 |
| Friedman, JH | 1 |
| Johnson, KH | 1 |
| Caton, H | 1 |
| Seidl, JJ | 1 |
| Layde, P | 1 |
| Fresquet, A | 1 |
| Sust, M | 1 |
| Lloret, A | 1 |
| Murphy, MF | 1 |
| Carter, FJ | 1 |
| Campbell, GM | 1 |
| Marion-Landais, G | 1 |
| Hébert, M | 1 |
| Longo, LP | 1 |
| Campbell, T | 1 |
| Hubatch, S | 1 |
| Roberts, J | 1 |
| Wang, W | 1 |
| Trachtenberg, D | 1 |
| Bitar, J | 1 |
| Lakier, J | 1 |
| Goldstein, S | 1 |
| Deshmukh, A | 1 |
| Wittert, W | 1 |
| Schnitzler, E | 1 |
| Mangurten, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder[NCT00624780] | Phase 4 | 615 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit[NCT04156464] | Phase 4 | 142 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics[NCT00809146] | Phase 3 | 1,023 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Effect of Bupropion on Seizure Threshold in Depressed Patients[NCT03126682] | Phase 4 | 10 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -2.3 |
| Pregabalin Low Dose | -2.1 |
| Lorazepam | -2.1 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -2.4 |
| Pregabalin High Dose, Placebo | -2.3 |
| Pregabalin Low Dose, Pregabalin Low Dose | -2.4 |
| Pregabalin Low Dose, Placebo | -2.0 |
| Lorazepam, Lorazepam | -2.5 |
| Lorazepam, Placebo | -2.2 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -12.0 |
| Pregabalin Low Dose | -5.9 |
| Lorazepam | -9.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -15.6 |
| Pregabalin Low Dose | -14.9 |
| Lorazepam | -16.0 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -16.6 |
| Pregabalin High Dose, Placebo | -19.1 |
| Pregabalin Low Dose, Pregabalin Low Dose | -18.3 |
| Pregabalin Low Dose, Placebo | -16.0 |
| Lorazepam, Lorazepam | -16.7 |
| Lorazepam, Placebo | -18.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -17.4 |
| Pregabalin Low Dose | -16.0 |
| Lorazepam | -16.7 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | -18.7 |
| Pregabalin High Dose, Placebo | -17.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | -18.2 |
| Pregabalin Low Dose, Placebo | -14.9 |
| Lorazepam, Lorazepam | -19.0 |
| Lorazepam, Placebo | -17.5 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | -2.0 |
| Pregabalin Low Dose | -2.7 |
| Lorazepam | -3.2 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | 2.1 |
| Pregabalin Low Dose | 2.0 |
| Lorazepam | 1.6 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 2.8 |
| Pregabalin High Dose, Placebo | -1.0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 1.7 |
| Pregabalin Low Dose, Placebo | 1.8 |
| Lorazepam, Lorazepam | 2.2 |
| Lorazepam, Placebo | -0.1 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. (NCT00624780)
Timeframe: Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose | 1.9 |
| Pregabalin Low Dose | 1.9 |
| Lorazepam | 1.9 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. (NCT00624780)
Timeframe: Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 1.7 |
| Pregabalin High Dose, Placebo | 1.9 |
| Pregabalin Low Dose, Pregabalin Low Dose | 1.6 |
| Pregabalin Low Dose, Placebo | 2.3 |
| Lorazepam, Lorazepam | 1.5 |
| Lorazepam, Placebo | 2.0 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose | 1 |
| Pregabalin Low Dose | 5 |
| Lorazepam | 1 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose | 3 |
| Pregabalin Low Dose | 1 |
| Lorazepam | 2 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | participants (Number) |
|---|---|
| Pregabalin High Dose, Pregabalin High Dose | 4 |
| Pregabalin High Dose, Placebo | 0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 0 |
| Pregabalin Low Dose, Placebo | 1 |
| Lorazepam, Lorazepam | 6 |
| Lorazepam, Placebo | 0 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=15,19,21) | Change at Discontinuation Week 1 (n=15,19,18) | |
| Lorazepam | 24.4 | -9.9 |
| Pregabalin High Dose | 25.8 | -7.7 |
| Pregabalin Low Dose | 24.9 | -5.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Discontinuation Week 1 | |
| Lorazepam | 24.6 | -15.8 |
| Pregabalin High Dose | 25.0 | -15.3 |
| Pregabalin Low Dose | 24.7 | -15.3 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Discontinuation Week 1 | |
| Lorazepam, Lorazepam | 24.6 | -16.2 |
| Lorazepam, Placebo | 24.9 | -19.1 |
| Pregabalin High Dose, Placebo | 24.2 | -18.7 |
| Pregabalin High Dose, Pregabalin High Dose | 25.5 | -17.6 |
| Pregabalin Low Dose, Placebo | 24.9 | -16.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 24.7 | -18.4 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=14,19,21) | Change at Discontinuation Week 1 (n=14,19,18) | Change at Discontinuation Week 2 (n=13,15,16) | |
| Lorazepam | 16.4 | -5.9 | -5.4 |
| Pregabalin High Dose | 13.6 | -3.4 | -4.7 |
| Pregabalin Low Dose | 17.6 | -3.3 | -2.7 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=57,51,52) | Change at Discontinuation Week 1 (n=57,51,49) | Change at Discontinuation Week 2 (n=53,48,44) | |
| Lorazepam | 14.8 | -7.6 | -8.0 |
| Pregabalin High Dose | 17.4 | -8.5 | -8.3 |
| Pregabalin Low Dose | 17.1 | -9.3 | -8.7 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=109,30,94,29,99,30) | Change at DC Week 1 (n=109,30,94,29,99,30) | Change at DC Week 2 (n=106,29,84,26,92,30) | |
| Lorazepam, Lorazepam | 16.8 | -8.7 | -9.6 |
| Lorazepam, Placebo | 14.9 | -10.4 | -10.3 |
| Pregabalin High Dose, Placebo | 17.8 | -12.9 | -13.8 |
| Pregabalin High Dose, Pregabalin High Dose | 17.8 | -11.0 | -9.8 |
| Pregabalin Low Dose, Placebo | 17.4 | -9.9 | -10.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 16.1 | -11.0 | -10.8 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=15,18,20) | Change at Discontinuation Week 1 (n=15,18,18) | Change at Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 16.1 | -2.4 | -2.2 |
| Pregabalin High Dose | 16.1 | 2.0 | -2.3 |
| Pregabalin Low Dose | 21.6 | -2.3 | -3.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=58,52,50) | Change at Discontinuation Week 1 (n=58,52,48) | Change at Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 6.7 | 2.3 | 1.5 |
| Pregabalin High Dose | 8.0 | 1.7 | 1.5 |
| Pregabalin Low Dose | 8.5 | 0.9 | 1.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Last visit on treatment (n=109,30,93,29,100,30) | Change at DC Week 1 (n=109,30,93,28,99,30) | Change at DC Week 2 (n=107,29,84,26,94,30) | |
| Lorazepam, Lorazepam | 5.6 | 3.0 | 2.2 |
| Lorazepam, Placebo | 5.5 | 0.3 | 0.6 |
| Pregabalin High Dose, Placebo | 5.5 | -0.0 | -0.8 |
| Pregabalin High Dose, Pregabalin High Dose | 6.3 | 1.6 | 2.5 |
| Pregabalin Low Dose, Placebo | 8.3 | 0.6 | 1.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 5.6 | 0.7 | 1.2 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment (n=15,18,20) | Change at Discontinuation Week 1 (n=15,18,18) | |
| Lorazepam | 13.1 | -4.2 |
| Pregabalin High Dose | 10.1 | 0.1 |
| Pregabalin Low Dose | 16.8 | -2.8 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment | Change at Discontinuation Week 1 | |
| Lorazepam | 5.0 | 2.3 |
| Pregabalin High Dose | 7.2 | 1.9 |
| Pregabalin Low Dose | 6.5 | 1.4 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Last visit on treatment | Change at Discontinuation Week 1 | |
| Lorazepam, Lorazepam | 5.3 | 3.0 |
| Lorazepam, Placebo | 4.7 | -0.1 |
| Pregabalin High Dose, Placebo | 4.9 | 0.0 |
| Pregabalin High Dose, Pregabalin High Dose | 5.2 | 1.7 |
| Pregabalin Low Dose, Placebo | 6.5 | 1.0 |
| Pregabalin Low Dose, Pregabalin Low Dose | 3.9 | 1.1 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Lorazepam | 4.4 | 2.3 |
| Pregabalin High Dose | 4.6 | 2.3 |
| Pregabalin Low Dose | 4.5 | 2.5 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Lorazepam, Lorazepam | 4.4 | 1.9 |
| Lorazepam, Placebo | 4.5 | 2.4 |
| Pregabalin High Dose, Placebo | 4.5 | 2.2 |
| Pregabalin High Dose, Pregabalin High Dose | 4.7 | 2.3 |
| Pregabalin Low Dose, Placebo | 4.5 | 2.5 |
| Pregabalin Low Dose, Pregabalin Low Dose | 4.5 | 2.1 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 14.1 | 14.6 |
| Pregabalin High Dose | 18.1 | 13.9 |
| Pregabalin Low Dose | 19.0 | 18.6 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=58,52,48) | Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 8.8 | 8.3 |
| Pregabalin High Dose | 9.6 | 9.0 |
| Pregabalin Low Dose | 9.4 | 9.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=109,30,94,28,99,30) | Discontinuation Week 2 (n=107,29,84,26,94,30) | |
| Lorazepam, Lorazepam | 8.4 | 7.9 |
| Lorazepam, Placebo | 7.07 | 6.1 |
| Pregabalin High Dose, Placebo | 5.5 | 5.0 |
| Pregabalin High Dose, Pregabalin High Dose | 7.9 | 8.9 |
| Pregabalin Low Dose, Placebo | 8.4 | 9.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 6.3 | 6.5 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Lorazepam | 24.5 | 7.9 |
| Pregabalin High Dose | 25.3 | 8.0 |
| Pregabalin Low Dose | 24.9 | 8.9 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected. (NCT00624780)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Lorazepam, Lorazepam | 24.7 | 5.7 |
| Lorazepam, Placebo | 24.1 | 6.6 |
| Pregabalin High Dose, Placebo | 24.6 | 7.1 |
| Pregabalin High Dose, Pregabalin High Dose | 25.6 | 7.0 |
| Pregabalin Low Dose, Placebo | 25.1 | 10.2 |
| Pregabalin Low Dose, Pregabalin Low Dose | 24.8 | 6.5 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam | 3 | 0 |
| Pregabalin High Dose | 6 | 0 |
| Pregabalin Low Dose | 0 | 0 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam | 36 | 1 |
| Pregabalin High Dose | 40 | 1 |
| Pregabalin Low Dose | 38 | 2 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2. (NCT00624780)
Timeframe: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | participants (Number) | |
|---|---|---|
| Newly developed DESS | Worsened DESS | |
| Lorazepam, Lorazepam | 50 | 5 |
| Lorazepam, Placebo | 7 | 0 |
| Pregabalin High Dose, Placebo | 5 | 0 |
| Pregabalin High Dose, Pregabalin High Dose | 78 | 2 |
| Pregabalin Low Dose, Placebo | 17 | 1 |
| Pregabalin Low Dose, Pregabalin Low Dose | 35 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state. (NCT00624780)
Timeframe: Baseline up to Week 12 (period 1), Week 13 up to Week 24 (period 2)
| Intervention | participants (Number) | |
|---|---|---|
| Period 1 (n=154,52,154,52,153,50) | Period 2 (n=121,39,112,38,114,39) | |
| Lorazepam, Lorazepam | 95 | 52 |
| Lorazepam, Placebo | 35 | 20 |
| Pregabalin High Dose, Placebo | 37 | 26 |
| Pregabalin High Dose, Pregabalin High Dose | 103 | 62 |
| Pregabalin Low Dose, Placebo | 40 | 18 |
| Pregabalin Low Dose, Pregabalin Low Dose | 100 | 62 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | Discontinuation Week 2 (n=14,15,16) | |
| Lorazepam | 9.1 | 10.6 |
| Pregabalin High Dose | 10.2 | 8.2 |
| Pregabalin Low Dose | 14.3 | 14.1 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=58,52,49) | Discontinuation Week 2 (n=54,49,44) | |
| Lorazepam | 7.3 | 6.9 |
| Pregabalin High Dose | 9.1 | 8.9 |
| Pregabalin Low Dose | 8.0 | 8.3 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected. (NCT00624780)
Timeframe: Week 1, 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Discontinuation Week 1 (n=109,30,94,29,99,30) | Discontinuation Week 2 (n=106,29,84,26,93,30) | |
| Lorazepam, Lorazepam | 8.0 | 7.1 |
| Lorazepam, Placebo | 4.6 | 4.6 |
| Pregabalin High Dose, Placebo | 4.9 | 4.1 |
| Pregabalin High Dose, Pregabalin High Dose | 6.8 | 7.9 |
| Pregabalin Low Dose, Placebo | 7.4 | 7.1 |
| Pregabalin Low Dose, Pregabalin Low Dose | 5.1 | 5.7 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Continuous acute care inpatient hospital days from day of admission until discharge (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | days (Mean) |
|---|---|
| IM Midazolam | 6.7 |
| IV Lorazepam | 5.5 |
Continuous days of initial ICU stay from time of admission (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | days (Mean) |
|---|---|
| IM Midazolam | 5.7 |
| IV Lorazepam | 4.1 |
Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT00809146)
Timeframe: at time of disposition on day of enrollment
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 128 |
| IV Lorazepam | 161 |
Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT00809146)
Timeframe: at ED disposition on day of enrollment
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 258 |
| IV Lorazepam | 292 |
Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation. (NCT00809146)
Timeframe: anytime before 30 minutes after ED arrival
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 63 |
| IV Lorazepam | 64 |
Acute hypotension is defined as a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 12 |
| IV Lorazepam | 13 |
IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 4 |
| IV Lorazepam | 2 |
IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care. (NCT00809146)
Timeframe: participants were followed for the duration of hospital stay, an average of 6 days
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 0 |
| IV Lorazepam | 3 |
Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival. (NCT00809146)
Timeframe: within 12 hours after ED arrival
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 51 |
| IV Lorazepam | 47 |
The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing. (NCT00809146)
Timeframe: Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).
| Intervention | participants (Number) |
|---|---|
| IM Midazolam | 329 |
| IV Lorazepam | 282 |
Scoring of depressive symptoms on the Montgomery Asberg Depression Rating Scale, maximum 60 , minimum 0. Higher scores mean worse outcome. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Scored on day 1 and day 2 after ECT session
| Intervention | Scored on a scale (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 2.60 |
| Wellbutrin During ECT 2 | 3.60 |
Duration of seizures with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | seconds (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 26.2 |
| Wellbutrin During ECT 2 | 29.6 |
Charge in Millicoulombs at which subject gets a seizure with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | millicoulombs (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 23.04 |
| Wellbutrin During ECT 2 | 19.68 |
4 reviews available for lorazepam and Recrudescence
| Article | Year |
|---|---|
Catatonia in systemic lupus erythematosus: a case report and review of literature.
Topics: Anti-Anxiety Agents; Catatonia; Female; Follow-Up Studies; Humans; Lorazepam; Lupus Erythematosus, S | 2013 |
[Venlafaxine-induced delirium mediated by high doses].
Topics: Aged; Antidepressive Agents; Comorbidity; Confusion; Delirium; Depressive Disorder, Major; Dopamine; | 2015 |
Treatment of status epilepticus in children.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Benzodiazepines; Central Nervous System Disea | 1996 |
9 trials available for lorazepam and Recrudescence
| Article | Year |
|---|---|
Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Dose-Response Relationship, Drug; D | 2014 |
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.
Topics: Adult; Alcohol Drinking; Amines; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Doub | 2009 |
A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal.
Topics: Administration, Oral; Alcohol-Related Disorders; Chlordiazepoxide; Female; GABA Modulators; Humans; | 2011 |
Intramuscular versus intravenous therapy for prehospital status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Emergency Medical | 2012 |
Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the consortium for research in electroconvulsive therapy.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Menta | 2007 |
Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
Topics: Adult; Agoraphobia; Anti-Anxiety Agents; Double-Blind Method; Female; Humans; Lorazepam; Male; Middl | 2000 |
[Can lorazepam prevent recurrent epileptic crises induced by alcohol?].
Topics: Adult; Alcohol Withdrawal Seizures; Anticonvulsants; Double-Blind Method; Humans; Infusions, Intrave | 2000 |
Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Anti-Anxiety Agents; Anticonvulsant | 2002 |
The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification.
Topics: Adult; Affect; Alcoholism; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Carbamazepine; Double-Blin | 2002 |
30 other studies available for lorazepam and Recrudescence
| Article | Year |
|---|---|
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
Recurring catatonia due to varying causes: A case report.
Topics: Catatonia; Humans; Lorazepam; Recurrence | 2021 |
Resurgence of catatonia following tapering or stoppage of lorazepam - A case series and implications.
Topics: Adult; Catatonia; Female; GABA Modulators; Humans; Lorazepam; Male; Psychotic Disorders; Recurrence; | 2017 |
Recurrent stress across life may improve cognitive performance in individual rats, suggesting the induction of resilience.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Cognition; Depression; Disease Models, Animal; Loraz | 2019 |
Synthetic marijuana use and development of catatonia in a 17-year-old male.
Topics: Adolescent; Cannabinoids; Cannabis; Catatonia; Designer Drugs; Electroconvulsive Therapy; Humans; Il | 2014 |
Lorazepam v. diazepam for pediatric status epilepticus.
Topics: Anticonvulsants; Child, Preschool; Diazepam; Female; Humans; Infant; Lorazepam; Male; Randomized Con | 2016 |
Topiramate augmentation in a patient with obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Citalopram; Drug Synergism; Fear; Female; Fructose; Hum | 2015 |
Relapses and recurrences of catatonia: 30-case analysis and literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Catatonia; Clozapine; Depressive Disorder | 2016 |
Maintenance lorazepam for treatment of recurrent catatonic states: A case series and implications.
Topics: Adolescent; Adult; Catatonia; Female; Humans; Lorazepam; Male; Recurrence; Young Adult | 2016 |
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Antihypertensive Agents; Ataxia; Cerebellum; Dose-Res | 2009 |
Recurrent opisthotonus in catatonia: An atypical presentation.
Topics: Adult; Catatonia; Diagnosis, Differential; Dystonia; Electroconvulsive Therapy; GABA Modulators; Hum | 2009 |
A tendency for re-offending in drug-facilitated crime.
Topics: Adult; Anti-Anxiety Agents; Chromatography, Liquid; Clonazepam; Crime Victims; Doxylamine; Drug Comb | 2010 |
The curious case of a catatonic patient.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Catatonia; Combined Modality Therapy; Delayed-Acti | 2011 |
Catatonia associated with hyponatremia treated with electroconvulsive therapy.
Topics: Adrenal Insufficiency; Anticonvulsants; Catatonia; Dehydration; Electroconvulsive Therapy; Female; H | 2012 |
[Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].
Topics: Adolescent; Benzodiazepines; Carbamazepine; Clonazepam; Clozapine; Creatine Kinase; Diagnosis, Diffe | 2013 |
Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report.
Topics: Adult; Catatonia; Chronic Disease; Echolalia; Female; Humans; Hypnotics and Sedatives; Lorazepam; Re | 2004 |
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.
Topics: Acute Disease; Aged; Benzodiazepines; Cognition Disorders; Delusions; Diagnosis, Differential; Diagn | 2006 |
Topiramate effect in catatonia: a case series.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cataplexy; Catatonia; Dose-Res | 2006 |
A closer look: the benefits and effectiveness of cognitive behavioral therapy on a female-specific unit for treatment of bipolar disorder.
Topics: Adult; Bipolar Disorder; Cognitive Behavioral Therapy; Female; Health Knowledge, Attitudes, Practice | 2007 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Clinical aspects of chronic use of alprazolam and lorazepam.
Topics: Alprazolam; Ambulatory Care; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; F | 1995 |
Relapse in a clozapine responder following lorazepam withdrawal.
Topics: Adult; Clozapine; Drug Therapy, Combination; Humans; Lorazepam; Male; Recurrence; Schizophrenia, Par | 1993 |
Exceptionally high seizure threshold: ECT device limitations.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Bipolar Disorder; Depressive Disorder; Electroconvulsi | 1996 |
Suspected covert lorazepam administration misdiagnosed as recurrent endozepine stupor.
Topics: Anti-Anxiety Agents; Carrier Proteins; Coma; Diagnostic Errors; Diazepam Binding Inhibitor; Electroe | 1998 |
Catatonia responsive to lorazepam: a case report.
Topics: Aged; Bipolar Disorder; Catatonia; Diagnosis, Differential; Female; Hip Fractures; Humans; Lorazepam | 1999 |
Initial treatment of generalized convulsive status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Diazepam; Double-Blind Method; Electroencephalography; Emergenci | 1999 |
Lorazepam to prevent alcohol withdrawal seizures.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Chronic Disease; Double-Blind Method; Emergency Service, Hos | 1999 |
Hyperemesis gravidarum treated with lorazepam.
Topics: Adult; Female; Humans; Hyperemesis Gravidarum; Lorazepam; Pregnancy; Recurrence | 1991 |
General anesthesia for intractable ventricular tachycardia.
Topics: Adult; Anesthesia, General; Humans; Lorazepam; Male; Morphine; Recurrence; Tachycardia | 1988 |
Lorazepam in the treatment of refractory neonatal seizures. A pilot study.
Topics: Electroencephalography; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Lorazepam; Mal | 1986 |